How it All Plays Out: Research Reports on Align Technology, Alimera, Alkermes, Alliance HealthCare Services, and Allied Healthcare Products

NEW YORK, February 3, 2015 /PRNewswire/ --

Moments ago, Analysts Review released new research updates concerning several important developing situations including Align Technology (NASDAQ: ALGN), Alimera (NASDAQ: ALIM), Alkermes (NASDAQ: ALKS), Alliance HealthCare Services, (NASDAQ: AIQ), and Allied Healthcare Products (NASDAQ: AHPI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

ALGN Research Report: ( http://get.analystsreview.com/pdf/?c=Align%20Technology&d=03-Feb-2015&s=ALGN ),

ALIM Research Report: ( http://get.analystsreview.com/pdf/?c=Alimera&d=03-Feb-2015&s=ALIM ),

ALKS Research Report: ( http://get.analystsreview.com/pdf/?c=Alkermes&d=03-Feb-2015&s=ALKS ),

AIQ Research Report: ( http://get.analystsreview.com/pdf/?c=Alliance%20HealthCare%20Services&d=03-Feb-2015&s=AIQ ),

AHPI Research Report: ( http://get.analystsreview.com/pdf/?c=Allied%20Healthcare%20Products&d=03-Feb-2015&s=AHPI ).

============

--

Analyst Update: Financial Results, Innovations, Marketing Authorizations, and Clinical Trial Results

Reviewed by: Rohit Tuli, CFA®  

The U.S. stocks ended higher on Monday helped by a late-session rally in the energy shares which also offset a fresh set of disappointing economic data. The Dow Jones Industrial Average rose 1.14% to close at 17,361.04, the S&P 500 increased 1.30% to close at 2,020.85, and the Nasdaq Composite gained 0.89% to end at 4,676.69. Energy shares led the advance, with the S&P 500 energy sector ending up nearly 3% following rise in the crude oil prices. Disappointing data on consumer spending and the manufacturing sector released on Monday weighed on the market early in the session. The European stocks ended on a mixed note on Monday amid continued uncertainty over Greece's debt negotiations and rising worries over the health of global economies. The pan-European Euro Stoxx 600 Index closed largely flat. In Asia, markets were mostly under pressure after fresh data raised concerns over China's manufacturing sector.

Align Technology, Inc. (Align Technology) expanded chairside CAD/CAM workflow options for the iTero intraoral scanner by announcing connectivity to IOS Technologies Inc., a wholly owned subsidiary of Glidewell Laboratories. According to the Company, the new workflow provides a broader spectrum of available CAD/CAM options to clinicians who wish to offer in-office same-day crowns, inlays, onlays and veneers.

Alimera Sciences, Inc. (Alimera) announced that it has received marketing authorization from the Finnish Medicines Agency in Finland and the Ministry of Health in Luxembourg for ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

Alkermes Plc (Alkermes) announced positive topline results from the 12-week, randomized, double-blind, active-controlled, dose-ranging stage of a phase II study of ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate designed to be a broad-spectrum treatment for schizophrenia.

Alliance HealthCare Services, Inc. reported a drop in Q3 2014 revenues of almost 3% YoY to $110.1 million, mostly due to decreases in MRI and PET/CT revenues, and other revenues, mostly attributed to the absence of professional radiology services revenue in Q3 2014, following the sale of its professional services business in December 2013.

Allied Healthcare Products, Inc. (Allied Healthcare Products) reported a marginal YoY increase in net sales to $8.8 million for Q1 FY 2015. Domestic sales were down 1.9% YoY while international sales, which represented 25.5% of first quarter sales, were up 13.4% YoY.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED